Form 4: Matinas BioPharma Director Keith Murphy Granted Stock Options

Director Keith Murphy receives stock options in Matinas BioPharma Holdings, Inc. subject to stockholder approval of the 2025 Equity Incentive Plan.

Summary

• Keith Murphy, a director of Matinas BioPharma Holdings, Inc., was granted stock options on April 30, 2025.
• The options allow Murphy to buy 11,600 shares of common stock at an exercise price of $0.59 per share.
• The options were granted under the Issuer's 2025 Equity Incentive Plan, which is subject to stockholder approval at the annual meeting on June 23, 2025.
• The options vest on April 30, 2026, contingent upon stockholder approval of the 2025 Plan.
• Following the transaction, Murphy directly owns 11,600 derivative securities.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices. The grant of options aligns the director's interests with shareholders, but the value is contingent on future stock performance and shareholder approval.

Positives

• The granting of stock options to a director aligns their interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the director.

Risks

• The stock options are subject to stockholder approval of the 2025 Equity Incentive Plan; failure to obtain approval would impact the vesting of the options.

Future Outlook

The vesting of the options is contingent on stockholder approval of the 2025 Equity Incentive Plan.

Industry Context

Stock option grants are a common form of executive compensation in the biopharmaceutical industry, aligning management's interests with shareholder value creation.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the pharmaceutical industry.
• Companies like Amgen, Gilead Sciences, and Biogen also use stock options to incentivize their directors and officers.
• The vesting schedules and exercise prices are generally structured to align with long-term performance goals.

Stakeholder Impact

• Shareholders: Potential dilution if options are exercised, but also alignment of director's interests with stock performance.
• Director: Incentive to improve company performance and increase shareholder value.

Next Steps

• Stockholder vote on the 2025 Equity Incentive Plan at the annual meeting on June 23, 2025.
• Vesting of the options on April 30, 2026, contingent upon stockholder approval.

Key Dates

Keywords

stock options, director, Matinas BioPharma, equity incentive plan, beneficial ownership, MTNB